|
Charles (Chuck) Newhall is a Co-Founder and General Partner of NEA. His investment activities focus on healthcare services, healthcare information services and biopharmaceutical companies. His board memberships include CoGenesys, ElderHealth, Hospital Partners of America, Sensors for Medicine & Science, TargetRx, Trine Pharmaceuticals, Vela Pharmaceuticals, and Vitae Pharmaceuticals. His prior board memberships include among others, AMERIGROUP, Caremark, Chomerics, Genetic Therapy, Life Technologies, PatientKeeper, Russ Pharmaceuticals, Scandipharm, Sepracor, Surgical Health, and Zymark Corporation. He is Founder of the Mid-Atlantic Venture Association. Before co-founding NEA, Mr. Newhall was a Vice President with T. Rowe Price Associates and Vice President of their New Horizons Fund. He received his MBA from the Harvard University Graduate School of Business and his BA in English Literature with honors from the University of Pennsylvania. | 